Literature DB >> 23879970

Association of an impaired bone marrow microenvironment with secondary poor graft function after allogeneic hematopoietic stem cell transplantation.

Yuan Kong1, Ying-Jun Chang, Ya-Zhe Wang, Yu-Hong Chen, Wei Han, Yu Wang, Yu-Qian Sun, Chen-Hua Yan, Feng-Rong Wang, Yan-Rong Liu, Lan-Ping Xu, Dai-Hong Liu, Xiao-Jun Huang.   

Abstract

Poor graft function (PGF) is a serious complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Whether abnormalities of the bone marrow (BM) microenvironment are involved in the pathogenesis of PGF is unclear. In the present prospective nested case-control study, 19 patients with secondary PGF, 38 matched patients with good graft function (GGF) after allo-HSCT, and 15 healthy donors (HDs) were enrolled. The cellular elements of the BM microenvironment, including endosteal cells, perivascular cells, and vascular cells, were analyzed by flow cytometry as well as hematoxylin and eosin and immunohistochemical staining in situ. The median time to occurrence of secondary PGF was 90 days post-transplantation (range, 58 to 264 days). The patients with PGF showed markedly hypocellular marrow (10% versus 45% versus 45%; P < .0001) with scattered hematopoietic cells and significantly lower CD34(+) cells (0.07% versus 0.26% versus 0.26%; P < .0001), endosteal cells (4 per high-power field [hpf] versus 16 per hpf versus 20 per hpf; P < .001), perivascular cells (0.008% versus 0.10% versus 0.12%; P < .0001), and endothelial progenitor cells (0.008% versus 0.16% versus 0.18%; P < .0001) compared with GGF allo-HSCT recipients and HDs, respectively. Multivariate analyses revealed that endothelial progenitor cells (odds ratio, 150.72; P = .001) and the underlying disease (odds ratio, 18.52; P = .007) were independent risk factors for secondary PGF. Our results suggest that the impaired BM microenvironment may contribute to the occurrence of secondary PGF post-HSCT.
Copyright © 2013 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Allogeneic hematopoietic stem cell transplantation; Bone marrow; Microenvironment; Poor graft function; Secondary

Mesh:

Year:  2013        PMID: 23879970     DOI: 10.1016/j.bbmt.2013.07.014

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  40 in total

1.  The bone marrow microenvironment is similarly impaired in allogeneic hematopoietic stem cell transplantation patients with early and late poor graft function.

Authors:  Y Kong; Y-T Wang; Y Hu; W Han; Y-J Chang; X-H Zhang; Z-F Jiang; X-J Huang
Journal:  Bone Marrow Transplant       Date:  2015-10-05       Impact factor: 5.483

2.  Early and late graft-failure after transplants.

Authors:  R P Gale
Journal:  Bone Marrow Transplant       Date:  2015-11-02       Impact factor: 5.483

3.  Presence of CD34(+)CD38(-)CD58(-) leukemia-propagating cells at diagnosis identifies patients at high risk of relapse with Ph chromosome-positive ALL after allo-hematopoietic SCT.

Authors:  Y Kong; L-P Xu; Y-R Liu; Y-Z Qin; Y-Q Sun; Y Wang; H Jiang; Q Jiang; H Chen; Y-J Chang; X-J Huang
Journal:  Bone Marrow Transplant       Date:  2014-12-08       Impact factor: 5.483

Review 4.  Improving the clinical outcome of unmanipulated haploidentical blood and marrow transplantation.

Authors:  Y-J Chang; X-J Huang
Journal:  Bone Marrow Transplant       Date:  2015-06       Impact factor: 5.483

5.  Incidence and risk factors of poor graft function after allogeneic stem cell transplantation for myelofibrosis.

Authors:  H Alchalby; D-R Yunus; T Zabelina; F Ayuk; N Kröger
Journal:  Bone Marrow Transplant       Date:  2016-04-18       Impact factor: 5.483

6.  Fresh or Cryopreserved CD34+-Selected Mobilized Peripheral Blood Stem and Progenitor Cells for the Treatment of Poor Graft Function after Allogeneic Hematopoietic Cell Transplantation.

Authors:  Armin Ghobadi; Mark A Fiala; Giridharan Ramsingh; Feng Gao; Camille N Abboud; Keith Stockerl-Goldstein; Geoffrey L Uy; Brenda J Grossman; Peter Westervelt; John F DiPersio
Journal:  Biol Blood Marrow Transplant       Date:  2017-03-18       Impact factor: 5.742

7.  Prophylactic use of low-dose interleukin-2 and the clinical outcomes of hematopoietic stem cell transplantation: A randomized study.

Authors:  Xiang-Yu Zhao; Xiao-Su Zhao; Yu-Tong Wang; Yu-Hong Chen; Lan-Ping Xu; Xiao-Hui Zhang; Wei Han; Huan Chen; Yu Wang; Chen-Hua Yan; Feng-Rong Wang; Jing-Zhi Wang; Kai-Yan Liu; Ying-Jun Chang; Xiao-Jun Huang
Journal:  Oncoimmunology       Date:  2016-10-28       Impact factor: 8.110

8.  Bone marrow regeneration promoted by biophysically sorted osteoprogenitors from mesenchymal stromal cells.

Authors:  Zhiyong Poon; Wong Cheng Lee; Guofeng Guan; Lin Myint Nyan; Chwee Teck Lim; Jongyoon Han; Krystyn J Van Vliet
Journal:  Stem Cells Transl Med       Date:  2014-11-19       Impact factor: 6.940

9.  Comparison of reference values for immune recovery between event-free patients receiving haploidentical allografts and those receiving human leukocyte antigen-matched sibling donor allografts.

Authors:  Xuying Pei; Xiangyu Zhao; Yu Wang; Lanping Xu; Xiaohui Zhang; Kaiyan Liu; Yingjun Chang; Xiaojun Huang
Journal:  Front Med       Date:  2017-09-08       Impact factor: 4.592

10.  Impairment of hematopoietic stem cell niches in patients with aplastic anemia.

Authors:  Liangliang Wu; Wenjian Mo; Yuping Zhang; Hui Deng; Yumiao Li; Ruiqing Zhou; Lu Zhang; Shiyi Pan; Shunqing Wang
Journal:  Int J Hematol       Date:  2015-10-06       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.